Additional Studies Indicate GlycoMark May Be a More Effective Monitor Than Hemoglobin A1C of Exenatide, Sitagliptin, Pramlintide and Prandial Insulin
Therapies in Certain Diabetic Populations
SAN FRANCISCO, June 7 /PRNewswire/ -- GlycoMark, Inc. announced today results from the ongoing DURABLE clinical trial showing that the GlycoMark blood test is a better reflection of glucose, particularly after-meal glucose levels, than the gold standard hemoglobin A1C test in moderately controlled patients with diabetes. These findings were reported by Kathleen Dungan, MD, of Ohio State University (Columbus, OH) and investigators from Eli Lilly (Indianapolis, IN) at the American Diabetes Association's 68th Annual Scientific Sessions (ADA) in San Francisco.
This is the largest clinical study to evaluate the clinical utility of GlycoMark to reflect after-meal glucose levels with 2,094 patients enrolled from 11 countries. The DURABLE trial (Assessing the Durability of Basal vs. Lispro Mix 75/25 Insulin Efficacy) confirms results from a smaller population study completed by John Buse, MD (University of North Carolina), Steven Wittlin, MD (University of Rochester), and Kathleen Dungan, MD, published in the medical journal Diabetes Care in June 2006.
In the study, the 1,5-Anhydroglucitol blood test (GlycoMark) correlated more strongly than hemoglobin A1C with all self-monitored plasma glucose (SMPG) parameters, particularly after-meal glucose levels, in moderately controlled patients with A1C levels less than 8.0%. Dr. Dungan concluded, "The data support the use of 1,5-anhydroglucitol, in conjunction with A1C, in moderately controlled patients with type 2 diabetes."
"This large clinical study validates the important role of the
GlycoMark test to effectively monitor patients with diabetes," said Eric
Button, President of GlycoMark, Inc. "Although patients may appear to be
adequately controlled by A1C results, it may not readily revea
|SOURCE GlycoMark, Inc.|
Copyright©2008 PR Newswire.
All rights reserved